Recent Updates
Recently added Catalysts
HCA Positive Sentiment

HCA Healthcare Reports Second Quarter 2026 Results

Friday, July 24, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: HCA Healthcare, Inc. reported its financial results for the second quarter of 2026, revealing an 8.7% increase in revenues compared to the same quarter in 2025. The company's net income attributable metrics were also highlighted, aligning with prior guidance shared on July 14, 2026. Overall, the results indicate a strong performance for the quarter.
Price reaction · baseline $376.5 (2026-07-23 close) · hit pre-market · clean, no other HCA news in the window
day 0 close · peak
+1.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Revenues increased by 8.7% to $20.230 billion.
  • Financial results are consistent with previous guidance.
  • Positive growth compared to the same quarter last year.

Full Press Release Details

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the second quarter ended June 30, 2026. The Company's financial and operating results, as well as its updated guidance and key assumptions, are consistent with its July 14, 2026 second quarter preview. Key second quarter metrics (all percentage changes compare 2Q 2026 to 2Q 2025 unless otherwise noted): Revenues increased 8.7 percent to $20.230 billion Net income attributable

Frequently Asked Questions

What were HCA Healthcare's Q2 2026 revenues?

HCA Healthcare reported revenues of $20.230 billion for Q2 2026.

How much did revenues increase compared to Q2 2025?

Revenues increased by 8.7% compared to Q2 2025.

When was HCA's second quarter preview released?

The second quarter preview was released on July 14, 2026.

What is the significance of the reported results?

The results indicate a strong financial performance for HCA Healthcare.

ShareAdd on Google
Tags: HCA Viatris Investor Conferences Healthcare HCA Healthcare Q2 2026 financial results revenue growth net income
Last updated: Jul 24, 2026

Biotech snapshot

Cash runway
$1415M liquidity · $0M/mo burn
Low dilution risk